Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
- Two new clinical trials, REFRaME-P1, a registration-enabling trial of luvelta for pediatric patients with rare leukemia, and REFRaME-L1, a Phase 2 trial of luvelta for patients with non-small cell lung cancer, are underway - Sutro presented data from the Phase 1b study of luvelta in combination with bevacizumab at ESMO 2024 demonstrating a 56% response rate at the recommended Phase 2 dose of luvelta (4.3 mg/kg) - - As of September 30, 2024, Sutro had $388.3 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the third quarter of 2024 and its recent business highlights. With its lead program, luveltamab tazevibulin (luvelta), Sutro recently initiated a registrational trial for a rare form of pediat
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire
- Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleGlobeNewswire
- Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless [Seeking Alpha]Seeking Alpha
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.MarketBeat
STRO
Earnings
- 11/13/24 - Beat
STRO
Sec Filings
- 12/10/24 - Form 8-K
- 12/3/24 - Form 4
- STRO's page on the SEC website